Galapagos (GLPG)

Executive Summary

Galapagos is a Belgian public biotechnology company focused on discovering and developing innovative small molecules and biologics for inflammation, fibrosis, and other diseases. The company's only marketed product is filgotinib (Jyseleca), a JAK1 inhibitor approved in Europe for rheumatoid arthritis and ulcerative colitis, which is partnered with AbbVie in the US (where it is not approved). Galapagos has been transitioning from a pure R&D organization to a fully integrated biopharmaceutical company, with ongoing efforts to build a pipeline of novel therapies. The company's pipeline includes early-stage candidates such as GLPG3970 (a dual SYK/TYK2 inhibitor) and GLPG3667 (a TYK2 inhibitor), targeting autoimmune indications, as well as cell therapy assets acquired through the purchase of CellPoint. Despite the decline in filgotinib sales due to competition and safety concerns, Galapagos is investing in new modalities and strategic partnerships to drive growth.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for GLPG3970 in ulcerative colitis55% success
• TBDFDA/EMA regulatory decision on filgotinib for a new indication (e.g., ankylosing spondylitis)30% success
• Q2 2026Announcement of a partnership or licensing deal for a preclinical CAR-T candidate40% success